Evidence map›Paper›PMID 29796999›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018

This is a call to oncologists for action.

C Micó, A Berrocal, A Blasco, C Caballero, V Iranzo, M Lobo, C Camps

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C MicóDepartment of Pharmacology, Faculty of Pharmacy, University of Valencia, Valencia, Spain. clara.mico.mateu04@gmail.com.ORCID http://orcid.org/0000-0002-6733-2443
A BerrocalMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
A BlascoMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
C CaballeroMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
V IranzoMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
M LoboMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
C CampsMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cases are growing in an exponential way, likewise the prices of new cancer drugs. Continuing in this way, in the near future, it will be impossible to provide optimum care for all cancer patients. Therefore, it is important to establish mechanisms that enable the National Health Systems to provide the best options of treatment, either through the elaboration of decision-binding frameworks or through other initiatives that guarantee the best quality care for all oncology patients to overcome, in the best possible way, this difficult illness. Here, we review current proposals that have been established by different cancer organizations worldwide, their similarities, their differences and whether they are helpful in a real clinical setting. Facing present reality and despite these organizations' huge efforts, these proposals are not being implemented at all and it does not seem feasible that they will in the short run. In the same way, we support and argue why oncologists should have a crucial and a preponderant role to establish the best way of guaranteeing an equal access to the latest oncology care.

Indexed as

Antineoplastic AgentsHumansMedical OncologyNeoplasmsAntineoplastic AgentsASCO scoreCancer costsCancer valueCanCon ProjectDrug AbacusESMO scoreEvidence blocksFrameworks toolsHealth costsHealth economicsOncologistsOncoSim

Identifiers

PMID29796999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.